Resat Cinar
@resatcinar.bsky.social
Scientist, Dad, Pharmacologist, Pharmacist, Researching on endocannabinoids, cannabinoid receptors, fibrotic disorders, and pulmonary fibrosis. Fibrosis researcher. Opinions are on my own view
🧵6️⃣ ⚡️Therapeutic modality to improve antifibrotic efficacy⚡️
📌 #Zevaquenabant treatment effectively reduces #fibrosis in human precision-cut lung slices (#hPCLS).
📌 Pulmonary delivery of zevaquenabant may offer a more targeted and safer #therapeutic modality for #fibrotic #lung #diseases
📌 #Zevaquenabant treatment effectively reduces #fibrosis in human precision-cut lung slices (#hPCLS).
📌 Pulmonary delivery of zevaquenabant may offer a more targeted and safer #therapeutic modality for #fibrotic #lung #diseases
July 3, 2025 at 6:20 PM
🧵6️⃣ ⚡️Therapeutic modality to improve antifibrotic efficacy⚡️
📌 #Zevaquenabant treatment effectively reduces #fibrosis in human precision-cut lung slices (#hPCLS).
📌 Pulmonary delivery of zevaquenabant may offer a more targeted and safer #therapeutic modality for #fibrotic #lung #diseases
📌 #Zevaquenabant treatment effectively reduces #fibrosis in human precision-cut lung slices (#hPCLS).
📌 Pulmonary delivery of zevaquenabant may offer a more targeted and safer #therapeutic modality for #fibrotic #lung #diseases
🧵5️⃣ ⚡️Therapeutic modality to improve antifibrotic efficacy⚡️
📌Systems #pharmacology reveals that #zevaquenabant and #nintedanib treatments reverse distinct and shared #pulmonaryfibrosis related pathways, provides opportunity for future clinical trials to improve clinical efficacy.
📌Systems #pharmacology reveals that #zevaquenabant and #nintedanib treatments reverse distinct and shared #pulmonaryfibrosis related pathways, provides opportunity for future clinical trials to improve clinical efficacy.
July 3, 2025 at 6:20 PM
🧵5️⃣ ⚡️Therapeutic modality to improve antifibrotic efficacy⚡️
📌Systems #pharmacology reveals that #zevaquenabant and #nintedanib treatments reverse distinct and shared #pulmonaryfibrosis related pathways, provides opportunity for future clinical trials to improve clinical efficacy.
📌Systems #pharmacology reveals that #zevaquenabant and #nintedanib treatments reverse distinct and shared #pulmonaryfibrosis related pathways, provides opportunity for future clinical trials to improve clinical efficacy.
🧵4️⃣ ⚡️Therapeutic modality to improve antifibrotic efficacy⚡️
📌 #Zevaquenabant attenuates multiple #fibrosis-related pathways in lungs
📌 Pulmonary delivery of zevaquenabant attenuated #fibrogenic #macrophages expressing Spp1, Trem2, Tgfb1, Mertk, Fabp5, Cd9, Cd63, Gpnmb, Fabp4
📌 #Zevaquenabant attenuates multiple #fibrosis-related pathways in lungs
📌 Pulmonary delivery of zevaquenabant attenuated #fibrogenic #macrophages expressing Spp1, Trem2, Tgfb1, Mertk, Fabp5, Cd9, Cd63, Gpnmb, Fabp4
July 3, 2025 at 6:20 PM
🧵4️⃣ ⚡️Therapeutic modality to improve antifibrotic efficacy⚡️
📌 #Zevaquenabant attenuates multiple #fibrosis-related pathways in lungs
📌 Pulmonary delivery of zevaquenabant attenuated #fibrogenic #macrophages expressing Spp1, Trem2, Tgfb1, Mertk, Fabp5, Cd9, Cd63, Gpnmb, Fabp4
📌 #Zevaquenabant attenuates multiple #fibrosis-related pathways in lungs
📌 Pulmonary delivery of zevaquenabant attenuated #fibrogenic #macrophages expressing Spp1, Trem2, Tgfb1, Mertk, Fabp5, Cd9, Cd63, Gpnmb, Fabp4
🧵3️⃣ ⚡️Therapeutic modality to improve safety ⚡️
📌🫁Pulmonary delivery of #zevaquenabant (#MRI1867) by lowering the systemic dose 20-fold retains superior therapeutic efficacy in mitigating PF by eliminating systemic exposure in animal model of #PulmonaryFibrosis
📌🫁Pulmonary delivery of #zevaquenabant (#MRI1867) by lowering the systemic dose 20-fold retains superior therapeutic efficacy in mitigating PF by eliminating systemic exposure in animal model of #PulmonaryFibrosis
July 3, 2025 at 6:20 PM
🧵3️⃣ ⚡️Therapeutic modality to improve safety ⚡️
📌🫁Pulmonary delivery of #zevaquenabant (#MRI1867) by lowering the systemic dose 20-fold retains superior therapeutic efficacy in mitigating PF by eliminating systemic exposure in animal model of #PulmonaryFibrosis
📌🫁Pulmonary delivery of #zevaquenabant (#MRI1867) by lowering the systemic dose 20-fold retains superior therapeutic efficacy in mitigating PF by eliminating systemic exposure in animal model of #PulmonaryFibrosis
🧵2️⃣ ⚡️Therapeutic target identification⚡️
📌 CB1R regulates #CD206-expressing macrophages and releases of #profibrotic mediators (IL-6, IL-4, LIF, GM-CSF, CXCL10, CCL7, CCL11, IGF-1).
📌 Inhibition of #CB1R in #AlveolarMacrophages attenuates #fibrogenic activation of Macrophages.
📌 CB1R regulates #CD206-expressing macrophages and releases of #profibrotic mediators (IL-6, IL-4, LIF, GM-CSF, CXCL10, CCL7, CCL11, IGF-1).
📌 Inhibition of #CB1R in #AlveolarMacrophages attenuates #fibrogenic activation of Macrophages.
July 3, 2025 at 6:20 PM
🧵2️⃣ ⚡️Therapeutic target identification⚡️
📌 CB1R regulates #CD206-expressing macrophages and releases of #profibrotic mediators (IL-6, IL-4, LIF, GM-CSF, CXCL10, CCL7, CCL11, IGF-1).
📌 Inhibition of #CB1R in #AlveolarMacrophages attenuates #fibrogenic activation of Macrophages.
📌 CB1R regulates #CD206-expressing macrophages and releases of #profibrotic mediators (IL-6, IL-4, LIF, GM-CSF, CXCL10, CCL7, CCL11, IGF-1).
📌 Inhibition of #CB1R in #AlveolarMacrophages attenuates #fibrogenic activation of Macrophages.
🧵1️⃣ ⚡️Therapeutic target identification ⚡️
📌 CB1R in #AlveolarMacrophages (AMs) is responsible to release #anandamide into #alveoli and to promote #fibrosis.
📌 CB1R in AMs plays a dominant role in pulmonary fibrosis by inducing fibrogenic macrophages.
📌 CB1R in #AlveolarMacrophages (AMs) is responsible to release #anandamide into #alveoli and to promote #fibrosis.
📌 CB1R in AMs plays a dominant role in pulmonary fibrosis by inducing fibrogenic macrophages.
July 3, 2025 at 6:20 PM
🧵1️⃣ ⚡️Therapeutic target identification ⚡️
📌 CB1R in #AlveolarMacrophages (AMs) is responsible to release #anandamide into #alveoli and to promote #fibrosis.
📌 CB1R in AMs plays a dominant role in pulmonary fibrosis by inducing fibrogenic macrophages.
📌 CB1R in #AlveolarMacrophages (AMs) is responsible to release #anandamide into #alveoli and to promote #fibrosis.
📌 CB1R in AMs plays a dominant role in pulmonary fibrosis by inducing fibrogenic macrophages.